Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Xiaoyao Powder is a Traditional Chinese Medicine (TCM) herbal formulation being evaluated for its therapeutic potential in treating chronic obstructive pulmonary disease (COPD) comorbid with mild to moderate depression. The formula is a modification of the classic Xiaoyao San (Free and Easy Wanderer), which is traditionally used to soothe the liver, strengthen the spleen, and nourish the blood. In clinical research conducted by the Hospital of Chengdu University of Traditional Chinese Medicine, this modified version is investigated for its ability to alleviate both respiratory symptoms and depressive symptoms, potentially through the modulation of the neuroendocrine-immune system and anti-inflammatory pathways. The modification typically involves the addition of specific herbs, such as *Gardenia jasminoides* and *Paeonia suffruticosa*, to the base formula of *Bupleurum chinense*, *Angelica sinensis*, *Paeonia lactiflora*, *Atractylodes macrocephala*, *Poria cocos*, and *Glycyrrhiza uralensis*.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Modified Xiaoyao Powder.